Beermann B, Ings R, Månsby J, Chamberlain J, McDonald A
Clin Pharmacol Ther. 1985 Jan;37(1):25-8. doi: 10.1038/clpt.1985.6.
The kinetics of a sustained-release formulation of pentoxifylline were compared with those of a capsule and an intravenous infusion. Ten healthy subjects received each of the oral pentoxifylline formulations (400 mg) three times a day for 9 days in a random crossover fashion. Pentoxifylline (200 mg) was also given intravenously on a separate day. After intravenous pentoxifylline, plasma levels declined in a biphasic manner, with a terminal t1/2 of 1.63 +/- 0.8 hr. Plasma clearance was 1333 +/- 481 ml/min and the volume of distribution was 168 +/- 82.3 l. Cumulation of pentoxifylline in plasma after repeated dosing was minimal. Plasma levels of the active 5-hydroxylated metabolite were generally higher than those of the parent drug after both routes of administration. Urinary excretion of two acid metabolites after oral and intravenous dosing indicated almost complete absorption of drug-related substances from both of the oral formulations, although bioavailability averaged 20% to 30%.
己酮可可碱缓释制剂的动力学与胶囊制剂和静脉输注制剂进行了比较。10名健康受试者以随机交叉方式,每天3次,每次服用口服己酮可可碱制剂(400毫克),共9天。在单独的一天还静脉注射了己酮可可碱(200毫克)。静脉注射己酮可可碱后,血浆水平呈双相下降,终末半衰期为1.63±0.8小时。血浆清除率为1333±481毫升/分钟,分布容积为168±82.3升。重复给药后血浆中己酮可可碱的蓄积量极小。两种给药途径后,活性5-羟基化代谢物的血浆水平通常高于母体药物。口服和静脉给药后两种酸性代谢物的尿排泄表明,两种口服制剂中与药物相关的物质几乎完全吸收,尽管生物利用度平均为20%至30%。